Pasireotide
FDA ApprovedA multi-receptor somatostatin analog FDA-approved for Cushing's disease and acromegaly. Features unique binding profile with 30-40 fold higher affinity for SSTR1 and SSTR5 compared to octreotide, enabling efficacy in patients resistant to first-generation somatostatin analogs.
SOM230 · Signifor · Signifor LAR
42 human studies
- Preclinical
- 13%
- Clinical
- 88%
Based on 48 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 92: multiple independent double-blind Phase 3 RCTs (Colao 2012 N=162 Cushing's 22397653; PAOLA Gadelha 2014 N=198 25260838; head-to-head Colao 2014 N=358 24423324) plus a 2026 systematic review + Bayesian network meta-analysis (41773305); pooled human N >1,000, direct population/route/outcome match (1A 35, 1B 23, 1C 14, 1D 15, 1E 5). Mechanism 95: SSTR1/2/3/5 targets with measured binding affinity and functional confirmation (Bruns 2002 11980628), full Gi/Go -> adenylyl-cyclase -> cAMP -> hormone-suppression pathway, dose-response across SC and LAR forms in vivo (2A 40, 2B 28, 2C 17, 2D 10). Plausibility 97: full mechanism -> surrogate (UFC, IGF-1) -> clinical-control chain, fully coherent with endocrine pathophysiology, same-class octreotide/lanreotide analogy, tightly scoped claims incl. on-target hyperglycemia (Henry 2013 23733372) (3A 38, 3B 25, 3C 20, 3D 14). Global Coverage 93: reproduced across many independent groups in 27+ countries, ~40+ pasireotide studies, multi- regulator approval (FDA/EMA) (4A 33, 4B 24, 4C 21, 4D 15). Community Experience 26: prescription rare-disease drug with negligible documented community use, >7-year clinical track record, no consistent community reports, hyperglycemia an expected managed AE (5A 4, 5B 15, 5C 0, 5D 7). Effectiveness clinical/high: Cushing's UFC normalization ~26% and acromegaly biochemical control 15-20% vs 0% on continued octreotide/lanreotide with head-to-head superiority in resistant patients, on biochemical surrogates (E1 16, E2 14, E3 8, E4 24 = 62).
The mechanisms of pasireotide are well-established through extensive clinical trials and receptor binding studies. Human mechanistic data is robust given FDA approval for multiple indications.
How It Works (Simplified)
Pasireotide mimics somatostatin, acting as a multi-receptor “brake” on hormone secretion:
Binds four somatostatin receptor subtypes (SSTR1, 2, 3, 5) with 30-40x higher SSTR5 affinity than octreotide, enabling efficacy in resistant tumors.
In Cushing’s disease, directly suppresses ACTH secretion from pituitary corticotroph adenomas via high SSTR5 affinity, lowering cortisol production.
In acromegaly, suppresses growth hormone secretion from somatotroph adenomas, leading to reduced hepatic IGF-1 production.
Inhibits insulin secretion via SSTR5 on pancreatic beta cells, causing hyperglycemia in 40-70% of patients requiring proactive management.
Key Research: Colao A et al. (2012) demonstrated 26.3% UFC normalization (900 mcg twice-daily arm) in the Cushing’s disease Phase 3 trial. PMID:22397653
Important Limitations
- Hyperglycemia occurs in 40-70% of patients, requiring proactive monitoring and management
- Higher cost compared to first-generation somatostatin analogs
- Not all patients respond despite multi-receptor targeting
- Contraindicated in severe hepatic impairment (Child-Pugh C)
Rapid suppression of hormone secretion begins. In Cushing's disease, ACTH reduction measurable within days. GH suppression in acromegaly occurs rapidly. Hyperglycemia may develop within first week - weekly FPG monitoring recommended.
PMID:22397653Continued hormone suppression. UFC levels decrease in Cushing's responders. IGF-1 reduction observed in acromegaly patients. Glucose levels typically stabilize or may require antidiabetic therapy initiation.
PMID:25260838Assessment of biochemical response at 2-3 months. Dose titration based on response and tolerability. Steady state achieved for LAR formulation. HbA1c monitoring every 3 months for hyperglycemia management.
PMID:24423324Full therapeutic response typically established. Tumor volume changes may be assessed. Long-term responders maintain biochemical control. Some patients develop tolerance requiring dose adjustment or combination therapy.
PMID:28597198Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Pegvisomant
SynergisticCombination studied in acromegaly. Pegvisomant blocks GH receptor while pasireotide suppresses GH secretion. May allow dose reduction of either agent with maintained efficacy.
Cabergoline
CompatibleDifferent mechanisms (dopamine agonist vs somatostatin analog). May be combined in resistant Cushing's disease or acromegaly. Monitor for additive effects on tumor shrinkage.
Metformin
CompatibleCommonly co-administered to manage pasireotide-induced hyperglycemia. First-line antidiabetic recommended per prescribing guidelines.
Insulin
CautionMay be required for pasireotide-induced hyperglycemia. Requires careful glucose monitoring as pasireotide directly suppresses insulin secretion via SSTR5.
Octreotide
AvoidSame drug class with overlapping receptor targets. No clinical rationale for combination as pasireotide provides broader SSTR coverage. Switching from octreotide to pasireotide is appropriate for resistant patients.
Lanreotide
AvoidSame drug class with overlapping receptor targets. No clinical rationale for combination. Pasireotide may be considered after lanreotide failure due to superior SSTR5 affinity.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Pasireotide
Related Peptides
CJC-1295
DAC:GRF · Modified GRF 1-29 · Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST · FS-344 · FS-315 +1
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6 · SKF-110679 · Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin · HEX · Growth Hormone Releasing Hexapeptide +2
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.